Ouster, Inc. (OUST)
Ouster, Inc. (OUST)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 48,578 | 62,178 | 39,525 | NaN |
| Product manufacturing costs | 22,499 | 19,642 | 17,815 | NaN |
| Stock based compensation and amortization expense | 1,689 | 1,368 | 2,086 | NaN |
| Other costs | 3,552 | 3,716 | 2,965 | NaN |
| Research and development | 16,082 | 15,261 | 17,777 | NaN |
| Sales and marketing | 7,840 | 6,782 | 7,441 | NaN |
| General and administrative | 16,128 | 14,505 | 15,692 | NaN |
| Total other income, net | 2,299 | 3,495 | 2,590 | NaN |
| Provision for income tax expense | 552 | 414 | 72 | NaN |
| Net loss | -17,465 | 3,985 | -21,733 | -42,629 |
| Depreciation and amortization | 2,703 | 2,074 | 2,053 | 3,654 |
| Loss on write-off and disposal of property and equipment and right-of-use asset impairment | NaN | NaN | 21 | 85 |
| Loss on write-off and disposal of property and equipment | 0 | 113 | NaN | NaN |
| Gain on lease termination | -65 | NaN | 0 | 65 |
| Stock-based compensation | 7,494 | 7,271 | 11,829 | 21,724 |
| Deferred taxes | 360 | NaN | NaN | NaN |
| Reduction of revenue related to stock warrant issued to customer | 1,101 | 569 | 1,033 | 1,021 |
| Amortization of right-of-use asset | 820 | 1,240 | 1,359 | 2,509 |
| Non-cash interest income | NaN | 214 | NaN | NaN |
| Accretion on short-term investments | 454 | 839 | 912 | 1,488 |
| Change in fair value of warrant liabilities | 0 | -118 | -237 | 229 |
| (recovery) provision for inventory write-down | -488 | 178 | -1,016 | 465 |
| Recovery of doubtful accounts | 0 | -128 | -17 | 137 |
| Realized gain on sale of investments | NaN | 12 | NaN | NaN |
| Realized gain on sale of available for sale securities | 5 | NaN | 0 | 4 |
| Accounts receivable | -6,472 | 5,087 | 9,401 | -6,471 |
| Inventory | 3,665 | 7,230 | 1,594 | -2,049 |
| Prepaid expenses and other assets | 153 | -2,374 | 2,303 | 3,640 |
| Accounts payable | -3,536 | 3,986 | 2,791 | 6,425 |
| Accrued and other liabilities | 134 | -11,921 | 2,078 | 3,978 |
| Contract liabilities | 1,020 | -9,925 | -538 | -3,836 |
| Operating lease liability | -895 | -1,705 | -1,755 | -3,273 |
| Net cash used in operating activities | -7,281 | -15,426 | -18,342 | -6,188 |
| Proceeds from sale of property & equipment | NaN | 0 | 0 | 0 |
| Purchases of property and equipment | 2,561 | 21,750 | 1,702 | 1,441 |
| Purchase of short-term investments | 10,802 | 31,189 | 38,738 | 79,686 |
| Proceeds from sales and maturities of short-term investments | 57,919 | 48,255 | 32,750 | 57,250 |
| Acquisition of stereolabs, net of cash acquired | 27,493 | NaN | NaN | NaN |
| Net cash provided by investing activities | 17,063 | -4,684 | -7,690 | -23,877 |
| Proceeds from espp purchase | NaN | 975 | 0 | 980 |
| Proceeds from exercise of stock options | 94 | 0 | 35 | 48 |
| Repayments of borrowings | NaN | 0 | 0 | NaN |
| Proceeds from the issuance of common stock under at-the-market offering, net of commissions and fees | NaN | 1,526 | 35,259 | 58,798 |
| At-the-market offering costs for the issuance of common stock | NaN | 189 | 222 | 10 |
| Payments received to fund employees tax obligation for vested rsus | 611 | -2,030 | 2,083 | 357 |
| Net cash provided by financing activities | 705 | 282 | 37,155 | 60,173 |
| Effect of exchange rates on cash and cash equivalents | 0 | 42 | -44 | 480 |
| Net increase in cash, cash equivalents and restricted cash | 10,487 | -19,786 | 11,079 | 30,588 |
| Cash, cash equivalents and restricted cash at beginning of period | 69,980 | 89,766 | 48,099 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 80,467 | 69,980 | 89,766 | NaN |